Corporate culture
Create a first-class enterprise, achieve a better future for employees, and create society
Company profile
塞力斯医疗科技集团股份有限公司
THALYS (stock code: 603716) was founded in February 2004, the company successfully listed on the capital market in October 2016, is the first medical intensive operation service provider listed on the main board of Shanghai Stock Market in central China, and is the pioneer of lean hospital management and smart medical new ecology in the industry.
Since 2020, the Group has launched the "Wuhan + Shanghai" dual headquarters model, and promoted the transformation and upgrading of traditional medical services to lean and intelligent through technological empowerment, business collaboration, strategic investment and other initiatives, and enabled by big data, blockchain, cloud computing, Internet of Things, AI and other information technologies. At the same time, strengthen industrial cooperation, integrate regional inspection center construction, SPD lean, IVD intensive system and local medical waste disposal system, and extend the layout of "PBM medical benefit management", "home medical HaD", "chronic disease co-insurance and long-term care insurance" and other out-of-hospital patient diagnosis and treatment scenarios. Build a "technology-enabled" whole-life health service platform that runs through in-hospital drug consumables, out-of-hospital patient treatment and insurance payments.
上海塞力斯医学检验实验室有限公司
THALYS MEDLAB was established in May 2021 and is an independent third-party medical laboratory approved by Shanghai Municipal Health Commission.
THALYS (stock code: 603716) is an independent medical testing service company, committed to providing customers with "total solution for medical diagnosis services", and actively promoting the expansion of third-party independent medical diagnosis platform in multiple service areas. Currently, it has: Nucleic acid mass spectrometry technology platform, high throughput sequencing platform, biochemical immunity technology platform, microbial identification technology platform, molecular diagnosis technology platform, etc. It can provide chronic disease management, endocrine and metabolic diagnosis, tumor marker screening, accurate diagnosis of CTC tumor and tumor drug detection on the basis of intestinal microecological gene map, full life cycle health management, microbial culture identification of bacteria, fungi and drug sensitivity test of sepsis, blood culture identification and comprehensive detection of molecular biology and immunology.
THALYS MEDLAB will provide "one-stop medical laboratory characteristic testing projects and diagnostic services", "Internet + Hospital Laboratory characteristic projects", "University research project transformation services" and "pharmaceutical enterprise Project LDT" for various medical laboratory laboratories, including medical institutions, medical communities, medical consortiums and medical groups Transformation service "and" Regional Public Service Testing Platform Service ", promote more top overseas high-end medical testing technologies to benefit China, help the rapid improvement of the inspection level of medical institution inspection centers, help hierarchical diagnosis and treatment and the implementation of the "Internet + medical" policy, and help realize the great strategy of healthy China!
Our Mission
Professional persistence, excellence, so that health can be held accurately.
- Help reduce the burden and cost of medical insurance to benefit the country and the people
- Explore medical reform innovation model to optimize resource allocation
- Achieve a better future for employees and create social value
-
核心价值观
Core Value
-
诚信
Integrity
-
团结
unity
-
创新
Innovation
-
激情
Passion
-
奋进
Keep Improving
愿景
Intelligent medical comprehensive system construction supplier based on artificial intelligence + medical big data
Development course
2022-02
Won the medical testing public service platform certification issued by Shanghai Baoshan District Science and Technology Committee
2022-03
THALYS MEDLAB granted Medical Institution License
2022-04
THALYS MEDLAB was awarded the technical audit and acceptance certificate of Clinical gene amplification Laboratory and the filing certificate of Shanghai Pathogenic Microbiology Laboratory (BSL-2) *
2023-05
THALYS successfully completed the online acceptance audit of Shanghai Baoshan District Health Commission and Municipal Inspection Center, successfully obtained the qualification of mobile shelter laboratory, and officially opened the cabin for operation
2023-05
THALYS MEDLAB was awarded the all-professional group license, covering all specialties such as blood and body fluids, clinical chemistry, clinical immunology, cell and molecular genetics, including gene testing, flow, coagulation and hemostasis, mass spectrometry, special immunity and other special testing platforms.
2022-06
THALYS MEDLAB Listed Shanghai Health Commission releases List of Qualified Third-party COVID-19 Nucleic Acid Testing Institutions in Shanghai
2023-12
THALYS MEDLAB is the first to cooperate with GA-map® and set up a research group in collaboration with several top research institutes in Central China, including Union Hospital of Tongji Medical College of Huazhong University of Science and Technology and Huazhong Agricultural University, to conduct multi-center research based on intestinal microecological characteristics of Chinese population
2023-01
THALYS MEDLAB partners with the unicorn of the molecular diagnostics industry to develop early diagnosis and risk stratification products for COVID-19 infection
2023-04
THALYS MEDLAB has signed a strategic cooperation agreement with Zhenxi Medical, a leader in fourth-generation gene sequencing technology
2023-04
THALYS MEDLAB is a new chapter in molecular genetic diagnosis
2023-06
THALYS MEDLAB and NanoString explore translational medicine and precision medicine innovation ecology
Honor and qualification
Strategic partner
上海衡道医学病理诊断中心有限公司
Hengdao Pathology is an independent third-party pathological diagnosis center with an area of nearly 3,000 square meters. It fully implements ISO 15189, CAP, CLIA and other industry standards and norms to meet the needs of routine pathological diagnosis, expert pathological consultation, remote intraoperative freezing diagnosis, and standardized services of pharmaceutical companies. Form a comprehensive pathology service solution combining online and offline, and realize the barrier-free sharing of high-quality pathology diagnosis resources across the country.
武汉臻熙医学检验实验室有限公司
Wuhan Zhenxi Medical Laboratory Co., LTD. (hereinafter referred to as "Zhenxi Medical") was established in 2018, located in the 5th floor of the East gate of the B21 building, Wuhan Optics Valley Medical Equipment Park, East Lake New Technology Development Zone, Wuhan. It is a high-tech startup company focused on applying genetic technology to the detection of pathogenic microorganisms. The company is committed to taking gene technology as the basis and targeted sequencing technology as the means, in-depth research and development, interdisciplinary innovation, continuous research and development in sample extraction, amplification, database construction, sequencing link to establish scientific and standard detection methods and technology platforms, promote the intelligence of data analysis, and finally submit for approval to complete standardized, easy to operate, widely used microbial diagnostic kits. It will perfectly combine the advantages of rapid and accurate gene technology to promote the technological iteration and upgrading of the microbial infection diagnosis industry, subvert the entire microbial detection industry, and provide more and more effective clinical choices for clinicians and patients.
In 2021, Zhenxi Medical has obtained the qualification recognition of high-tech enterprises, high-tech smes and science and technology small giants. In the same year, Dr. Fu Aisi, co-founder and Director of Research and development, was selected as the Innovative Talent of 3551 Optical Valley Talents.
广州嘉检医学检测有限公司
Guangzhou Jiachan Medical Testing Co., LTD. (hereinafter referred to as "Jiachan Medical") is committed to promoting the transformation and application of genomic testing technology in clinical practice. Under the guidance of the national precision Medicine plan, with the goal of reducing the rate of birth defects by 1%, with the mission of "localization, localization and specialization" of clinical genetics, we join hands with domestic and international experts in clinical genetics. And young and middle-aged clinical geneticists, to become the preferred partner of birth defect prevention and control.
Agency partner
